Please use this identifier to cite or link to this item:
Title: Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery.
Authors: Peta, Valentina
Tse, Chantal
Perazzo, Hugo
Munteanu, Mona
Ngo, Yen
Ngo, An
Ramanujam, Nittia
Verglas, Lea
Mallet, Maxime
Ratziu, Vlad
Thabut, Dominique
Rudler, Marika
Thibault, Vincent
Schuppe-Koistinen, Ina
Bonnefont-Rousselot, Dominique
Hainque, Bernard
Imbert-Bismut, Françoise
Merz, Michael
Kullak-Ublick, Gerd
Andrade, Raul
van Boemmel, Florian
Schott, Eckart
Poynard, Thierry
Drug Induced Liver Injury- Groupe Hospitalier Pitié-Salpêtrière
Drug Induced Liver Group of the Injury Safer and Faster Evidence-based Translation consortium
metadata.dc.subject.mesh: Apolipoprotein A-I
Chemical and Drug Induced Liver Injury
Middle Aged
Issue Date: 29-Dec-2017
Abstract: There is a clear need for better biomarkers of drug-induced-liver-injury (DILI). We aimed to evaluate the possible prognostic value of ActiTest and FibroTest proteins apoliprotein-A1, haptoglobin and alpha-2-macroglobulin, in patients with DILI. We analyzed cases and controls included in the IMI-SAFE-T-DILI European project, from which serum samples had been stored in a dedicated biobank. The analyses of ActiTest and FibroTest had been prospectively scheduled. The primary objective was to analyze the performance (AUROC) of ActiTest components as predictors of recovery outcome defined as an ALT After adjudication, 154 patients were considered to have DILI and 22 were considered to have acute liver injury without DILI. A multivariate regression analysis (ActiTest-DILI patent pending) combining the ActiTest components without BILI and ALT (used as references), apolipoprotein-A1, haptoglobin, alpha-2-macroglobulin and GGT, age and gender, resulted in a significant prediction of recovery with 67.0% accuracy (77/115) and an AUROC of 0.724 (P We identified that apolipoprotein-A1 and haptoglobin had significant predictive values for the prediction of recovery at 12 weeks in DILI, enabling the construction of a new prognostic panel, the DILI-ActiTest, which needs to be independently validated.
metadata.dc.identifier.doi: 10.1371/journal.pone.0189436
Appears in Collections:Producción 2020

Files in This Item:
File SizeFormat 
PMC5747433.pdf1,32 MBAdobe PDFView/Open

This item is protected by original copyright

This item is licensed under a Creative Commons License Creative Commons